Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma

References

• Allen TM, Cullis PR. (2004). Drug delivery systems: entering the mainstream. Science 303:1818–22
   PubMed Web of Science ®Google Scholar
• Bolotin EM, Cohen R, Bar LK, et al. (1994). Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res 4:455–79
   Google Scholar
• Brodin L, Low P, Shupliakov O. (2000). Sequential steps in clathrin-mediated synaptic vesicle endocytosis. Curr Opin Neurobiol 10:312–20
   PubMed Web of Science ®Google Scholar
• Carlsson J, Yuhas J. (1984). Liquid-overlay culture of cellular spheroids. Spheroids Cancer Res 1--23. DOI: http://dx.doi.org/10.1007/978-3-642-82340-4_1
   Google Scholar
• Chen AM, Zhang M, Wei D, et al. (2009). Co-delivery of Doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5:2673–7
   PubMed Web of Science ®Google Scholar
• Chen W, Meng F, Cheng R, Zhong Z. (2010). pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles. J Control Release 142:40–6
   PubMed Web of Science ®Google Scholar
• Daniels TR, Delgado T, Rodriguez JA, et al. (2006). The transferrin receptor, part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121:144–58
   PubMed Web of Science ®Google Scholar
• Eaveri R, Ben-Yehudah A, Lorberboum-Galski H. (2004). Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy. Curr Cancer Drug Targets 4:673–87
   PubMed Web of Science ®Google Scholar
• El-Sayed A, Futaki S, Harashima H. (2009). Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J 11:13–22
   PubMed Web of Science ®Google Scholar
• Fittipaldi A, Giacca M. (2005). Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev 57:597–608
   PubMed Web of Science ®Google Scholar
• Forssen EA, Coulter DM, Proffitt RT. (1992). Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52:3255–61
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Cao S, et al. (2014a). Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment. Biomaterials 35:2374–82
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Zhang S, et al. (2013). Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth. J Control Release 172:921–8
   PubMed Web of Science ®Google Scholar
• Gao HL, Yang Z, Zhang S, et al. (2014b). Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays. Acta Biomater 10:858–67
   PubMed Web of Science ®Google Scholar
• Jaracz S, Chen J, Kuznetsova LV, Ojima I. (2005). Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 13:5043–54
   PubMed Web of Science ®Google Scholar
• Joliot A, Prochiantz A. (2004). Transduction peptides: from technology to physiology. Nature Cell Biol 6:189–96
   PubMed Web of Science ®Google Scholar
• Kibria G, Hatakeyama H, Harashima H. (2011a). A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system. Int J Pharm 412:106–14
   PubMed Web of Science ®Google Scholar
• Kibria G, Hatakeyama H, Ohga N, et al. (2011b). Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release 153:141–8
   PubMed Web of Science ®Google Scholar
• Kuai R, Yuan W, Li W, et al. (2011). Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration. Mol Pharm 8:2151–61
   PubMed Web of Science ®Google Scholar
• Lee AL, Wang Y, Cheng HY, et al. (2009). The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 30:919–27
   PubMed Web of Science ®Google Scholar
• Lee S, Baek M, Kim H-Y, et al. (2002). Mechanism of doxorubicin-induced cell death and expression profile analysis. Biotechnol Lett 24:1147–51
   Web of Science ®Google Scholar
• Li X, Zhou H, Yang L, et al. (2011). Enhancement of cell recognition in vitro by dual-ligand cancer targeting gold nanoparticles. Biomaterials 32:2540–5
   PubMed Web of Science ®Google Scholar
• Liu YR, Fang JX, Kim YJ, et al. (2014). Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharm 11:1651–61
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–84
   PubMed Web of Science ®Google Scholar
• Maeda N, Takeuchi Y, Takada M, et al. (2004). Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release 100:41–52
   PubMed Web of Science ®Google Scholar
• Malam Y, Loizidou M, Seifalian AM. (2009). Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharm Sci 30:592–9
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M, et al. (1998). Vaccination of melanoma patients with peptide- or tumorly sate-pulsed dendritic cells. Nat Med 4:328–32
   PubMed Web of Science ®Google Scholar
• Pérez-Tomás R. (2006). Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13:1859–76
   PubMed Web of Science ®Google Scholar
• Qian ZM, Li H, Sun H, Ho K. (2002). Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54:561–87
   PubMed Web of Science ®Google Scholar
• Qin Y, Chen H, Zhang Q, et al. (2011). Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm 420:304–12
   PubMed Web of Science ®Google Scholar
• Salter-Cid L, Brunmark A, Li Y, et al. (1999). Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Proc Natl Acad Sci 96:5434–9
   PubMed Web of Science ®Google Scholar
• Saul JM, Annapragada AV, Bellamkonda RV. (2006). A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 114:277–87
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Koning GA, Ten Hagen TLM, et al. (2003). Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 91:115–22
   PubMed Web of Science ®Google Scholar
• Schutte B, Nuydens R, Geerts H, Ramaekers F. (1998). Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells. J Neurosci Methods 86:63–9
   PubMed Web of Science ®Google Scholar
• Senior J, Gregoriadis G. (1982). Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci 30:2123–36
   PubMed Web of Science ®Google Scholar
• Sharma G, Modgil A, Layek B, et al. (2013). Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection. J Control Release 167:1–10
   PubMed Web of Science ®Google Scholar
• Shew R, Deamer D. (1985). A novel method for encapsulation of macromolecules in liposomes. Biochim Biophys Acta 816:1–8
   PubMed Web of Science ®Google Scholar
• Stephenson SM, Low PS, Lee RJ. (2004). Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol 387:33–50
   PubMed Web of Science ®Google Scholar
• Suzuki R, Takizawa T, Kuwata Y, et al. (2008). Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 346:143–50
   PubMed Web of Science ®Google Scholar
• Takara K, Hatakeyama H, Kibria G, et al. (2012). Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. J Control Release 162:225–32
   PubMed Web of Science ®Google Scholar
• Takara K, Hatakeyama H, Ohga N, et al. (2010). Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. Int J Pharm 396:143–8
   PubMed Web of Science ®Google Scholar
• Tishler RB, Geard CR, Hall EJ, Schiff PB. (1992). Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495–7
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2008). TAT peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 60:548–58
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma S, Xie Z, Zhang H. (2014). A synergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles. Colloids Surf B: Biointerfaces 116:41–8
   PubMed Web of Science ®Google Scholar
• Warren RA, Green FA, Enns CA. (1997). Saturation of the endocytic pathway for the transferrin receptor does not affect the endocytosis of the epidermal growth factor receptor. J Biol Chem 272:2116–21
   PubMed Web of Science ®Google Scholar
• Watson K, Edwards RJ. (1999). HIV-1 trans-activating (Tat) protein: both a target and a tool in therapeutic approaches. Biochem Pharmacol 58:1521–8
   PubMed Web of Science ®Google Scholar
• Youn P, Chen Y, Furgeson DY. (2014). A myristoylated cell-penetrating peptide bearing a transferrin receptor-targeting sequence for neuro-targeted siRNA delivery. Mol Pharmaceut 11:486–95
   PubMed Web of Science ®Google Scholar
• Young SE, Martinez SR, Essner R. (2006). The role of surgery in treatment of stage IV melanoma. J Surg Oncol 94:344–51
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, et al. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83:761–9
   PubMed Web of Science ®Google Scholar
• Zong T, Mei L, Gao H, et al. (2014a). Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Mol Pharm 11:2346–57
   PubMed Web of Science ®Google Scholar
• Zong T, Mei L, Gao H, et al. (2014b). Enhanced glioma targeting and penetration by dual-targeting liposome co-modified with T7 and TAT. J Pharm Sci 103:3891–901
   PubMed Web of Science ®Google Scholar